Drug Information

Drug General Information
Drug ID
D0TU7V
Former ID
DIB014783
Drug Name
MB-12066
Synonyms
B-lapachone (obesity), Mazence; Beta-lapachone (obesity), Mazence
Indication Obesity [ICD9: 278; ICD10:E66] Phase 2 [524589]
Company
Mazence Inc
Target and Pathway
Target(s) NAD-dependent deacetylase sirtuin-1 Target Info Modulator
KEGG Pathway FoxO signaling pathway
AMPK signaling pathway
Glucagon signaling pathway
Amphetamine addiction
MicroRNAs in cancer
PANTHER Pathway p53 pathway
Pathway Interaction Database p73 transcription factor network
Signaling events mediated by HDAC Class III
E2F transcription factor network
HIF-2-alpha transcription factor network
Signaling events mediated by HDAC Class I
FoxO family signaling
Regulation of Androgen receptor activity
Regulation of retinoblastoma protein
Reactome RORA activates gene expression
Regulation of HSF1-mediated heat shock response
Circadian Clock
WikiPathways Integrated Pancreatic Cancer Pathway
SREBF and miR33 in cholesterol and lipid homeostasis
Integrated Breast Cancer Pathway
SREBP signalling
Androgen receptor signaling pathway
References
Ref 524589ClinicalTrials.gov (NCT02029586) Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.